Bezafibrate: effects on serum lipoproteins and haemostatic factors

  • D. Sommariva
  • A. Branchi
  • A. Rovellini
  • D. Bonfiglioli
  • L. Scandiani
  • C. Pini
  • M. Tirrito
  • A. Fasoli

Abstract

After a period of dietary stabilization 68 patients with primary hyperlipoproteinemia have been treated with bezafibrate 200 mg t.i.d.. Cholesterol (C) and triglycerides (TG) were measured in lipoprotein fractions before and after 1 month of therapy. In type IIa patients, the main change was a 23% decrease of LDL-C. LDL-TG and VLDL lipids also underwent a reduction. In type IIb patients both VLDL and LDL lipids significantly decreased. In type IV patients VLDL lipids decreased and LDL-C rose. HDL-C significantly increased in all groups of patients owing to an increase of HDL3-C, while the C content of HDL2 subfraction significantly increased only in hypertriglyceridemic patients (type IIb and IV). The change in VLDL and LDL lipids resulted to be positively correlated with their pretreatment value. Apoprotein B decreased by 24% in type IIa and by 29% in type IIb patients. Apoprotein A-I increased by 19% in type IIb patients and underwent a small and non significant increase in type IIa patients. The change in serum lipoprotein lipid concentration was associated with a change in lipoprotein lipid composition. C:TG ratio decreased in LDL of type IIa, increased in LDL of type IV and in HDL of all groups of patients. Plasma fibrinogen resulted to be 10% lower after 1 month of bezafibrate than before. The diminution was greater in patients with plasma fibrinogen higher than average and was not related with the changes in serum lipoprotein lipid concentration.

Keywords

Plasma Fibrinogen Serum Lipoprotein Hypercholesterolemic Patient Lipoprotein Lipid VLDL Cholesterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aimer, L.O. and Kjellstrom, T. (1986) ‘The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia.’ Atherosclerosis, 61, 81–85.CrossRefGoogle Scholar
  2. Arntz, H.R., Leonardt, H., Lang, P.D. and Vollmar, J. (1981) ‘Effects of bezafibrate and clofibrate on blood rheology and lipoproteins in primary hyperlipoproteinemia.’ Clin. Trial J., 18, 280–286.Google Scholar
  3. Beaumont, J.L., Carlson, L.A., Cooper, G.R., Fejfar, Z., Fredrickson, D.S. and Stratter, T. (1970) ‘Classification of hyperlipidemias and hyperlipoproteinemias.’ WHO Bull., 43, 891–909.Google Scholar
  4. Berndt, J., Gaumert, R. and Still, J. (1978) ’Mode of action of the lipid lowering agents clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. Atherosclerosis, 30, 147–152.Google Scholar
  5. Blasi, P., Soimariva, D., Cosentini R., Cavaiani, B. and Fasoli, A. (1989) ‘Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolemia.’ Pharmacol. Res., 21, 247–254PubMedCrossRefGoogle Scholar
  6. Clauss, A. (1957) ‘Rapid physiological coagulation method in determination of fibrinogen.’ Acta Haemat., 17, 237PubMedCrossRefGoogle Scholar
  7. Clauss, A. (1957) ‘Rapid physiological coagulation method in determination of fibrinogen.’ Acta Haemat., 17, 237PubMedCrossRefGoogle Scholar
  8. Eisenberg, S., Gavish, D., Oschry, Y., Fainaru, M. and Deckelbaum R.J. (1984) ‘Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.’ J. Clin. Invest., 74, 470–475.PubMedCrossRefGoogle Scholar
  9. Fellin, R., Martini, S., Crepaldi, G., Senin, U., Mannarino, E., Avellone, G., Notarbartolo, A., Capurso, A., D’Agostino, C., Montaguti, U., Celin, D., Descovich, G.C. and Mantovani, E. (1981) ‘Multicenter trial with bezafibrate in primary hyperlipidemias.’ Curr. Ther. Res., 29, 657–666.Google Scholar
  10. Klose, G., Behrendt, J., Vollmar, J and Greten, H. (1981) ‘Effect of bezafibrate on the activity of lipoprotein lipase and hepatic triglyceride hydrolase in healthy volunteers’, in H. Greten, P.D. Lang and G. Schettler (eds), Lipoprotein and Coronary Heart Disease, G. Witzstrock Publ. House, New York, Baden-Baden, Cologne, pp. 182–184.Google Scholar
  11. Kohlmeier, M. and Schlierf, G. (1982) ‘Mode of action of bezafibrate’, in G. Crepaldi, H. Schettler and G. Baggio (eds), Lipoprotein Metabolism and Therapy of Lipid Disorders, Excerpta Medica, Amsterdam, pp. 93–96.Google Scholar
  12. Lang, P.D., Holler, H.D. and Vollmar, J. (1982) ‘Tolerance of two years’ treatment with bezafibrate in patients with hyperlipidemia’, in G. Crepaldi, H. Schettler and G. Baggio (eds), Lipoprotein Metabolism and Therapy of Lipid Disorders, Excerpta Medica, Amsterdam, pp. 87–92.Google Scholar
  13. Niort, G., Bulgarelli, M., Cassader, M. and Pagano, G. (1988) ‘Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients.’ Atherosclerosis, 71, 113–119PubMedCrossRefGoogle Scholar
  14. Olsson, A.G., Lang, P.D. and Vollmar, J. (1985) ‘Effect of bezafibrate during 4.5 years treatment of hyperlipoproteinemia.’ Atherosclerosis, 55, 195–203.PubMedCrossRefGoogle Scholar
  15. Olsson, A.G., Rossner, S., Walldius, G., Carlson, L.A. and Lang, P.D. (1977) ‘Effect of BM 15075 on lipoprotein concentrations in different types of hyperlipoproteinemia.’ Atherosclerosis, 27, 279–287.PubMedCrossRefGoogle Scholar
  16. Smith, E.B. and Keen, G.A. (1987) ‘Haemostatic factors and lipoproteins in atherogenesis’, in S. Lenzi and G.C. Descovich (eds), Atherosclerosis and Cardiovascular Diseases, MTP Press, Lancaster, pp. 319–325.CrossRefGoogle Scholar
  17. Sonmariva, D., Tirrito, M., Bonfiglioli, D., Pogliaghi, I., Branchi, A. and Cabrini, E. (1986) ‘Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolemic patients.’ Int. J. Clin. Pharm. Res., 3, 249–253.Google Scholar
  18. Stewart, J.M., Packard, C.J., Lorimer, A.R., Boag, D.E. and Shepherd, J. (1982) ‘Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects.’ Atherosclerosis, 44, 355–365.PubMedCrossRefGoogle Scholar
  19. Zimmermann, R., Ehlers, W., Walter, E., Hoffrichter, A., Lang, P.D., Andrassy, K. and Schlierf G. (1978) ‘The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumon.’ Atherosclerosis, 29, 477–485PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • D. Sommariva
    • 1
  • A. Branchi
    • 2
  • A. Rovellini
    • 2
  • D. Bonfiglioli
    • 1
  • L. Scandiani
    • 2
  • C. Pini
    • 2
  • M. Tirrito
    • 1
  • A. Fasoli
    • 2
  1. 1.II Department of MedicineL. Sacco HospitalMilanItaly
  2. 2.Institute of Internal Medicine and Medical PhysiopathologyUniversity of MilanMilanItaly

Personalised recommendations